The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2023

Filed:

Jan. 06, 2017
Applicants:

Kyoto University, Kyoto, JP;

Km Biologics Co., Ltd., Kumamoto, JP;

Inventors:

Koichiro Hata, Kyoto, JP;

Shinji Uemoto, Kyoto, JP;

Hirofumi Hirao, Kyoto, JP;

Toyonari Kubota, Kyoto, JP;

Assignees:

KYOTO UNIVERSITY, Kyoto, JP;

KM BIOLOGICS CO., LTD., Kumamoto, JP;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/573 (2006.01); A61K 38/48 (2006.01); G01N 33/576 (2006.01);
U.S. Cl.
CPC ...
G01N 33/573 (2013.01); A61K 38/4886 (2013.01); G01N 33/576 (2013.01); G01N 2333/96494 (2013.01); G01N 2800/08 (2013.01); G01N 2800/085 (2013.01);
Abstract

New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.


Find Patent Forward Citations

Loading…